Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+ AML. We compared HLA class I distribution in NPMc+ AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+ AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.

• MeSH
• Leukemia, Myeloid, Acute * genetics   immunology   mortality   MeSH
• Immunity, Cellular * MeSH
• Adult MeSH
• Nuclear Proteins * genetics   immunology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Histocompatibility Antigens Class I * genetics   immunology   MeSH
• Survival Rate MeSH
• Neoplasm Proteins * genetics   immunology   MeSH
• Nucleophosmin MeSH
• Prevalence MeSH
• Disease-Free Survival MeSH
• Aged MeSH
• T-Lymphocytes immunology   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial MeSH
• Multicenter Study MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Nuclear Proteins * MeSH
• Histocompatibility Antigens Class I * MeSH
• Neoplasm Proteins * MeSH
• NPM1 protein, human MeSH Browser
• Nucleophosmin MeSH